SSRI drug interactions: the list by agent, the mechanism, and what to check before you prescribe

The one hard contraindication is a monoamine oxidase inhibitor (phenelzine, tranylcypromine, isocarboxazid, selegiline, and the antibiotic linezolid and the dye methylene blue, which are MAO inhibitors people forget about). Combining an SSRI with any of these can cause life-threatening serotonin syndrome, and the labeling requires a washout in both directions: at least 14 days between stopping an MAOI and starting an SSRI, at least 14 days after most SSRIs before an MAOI, and five weeks after fluoxetine because of its long half life.

Beyond the absolute contraindication, the combinations that most often cause harm are additive rather than forbidden: another serotonergic drug (tramadol, triptans, other antidepressants, St John's wort) raising serotonin syndrome risk, and an NSAID or anticoagulant raising bleeding risk. These are not reasons never to co-prescribe, but they are reasons to check, counsel, and sometimes choose a different agent.

By frequency, the CYP2D6 interactions of fluoxetine and paroxetine are the ones clinicians meet most often, because so many everyday drugs are 2D6 substrates. The clinically important version is the prodrug problem: codeine, tramadol and hydrocodone rely on CYP2D6 to convert to their active forms, so a patient on fluoxetine or paroxetine may get little analgesia from them. The mirror image is tamoxifen, which needs 2D6 to form its active metabolite endoxifen, so a strong 2D6-inhibiting SSRI can reduce its anticancer effect.

The other high-frequency interaction is pharmacodynamic bleeding risk. SSRIs deplete platelet serotonin, which impairs aggregation, so the combination of an SSRI with an NSAID, an antiplatelet or an anticoagulant raises the risk of gastrointestinal bleeding measurably. None of this shows up on a lab value; it shows up as a bleed. When a bleeding-risk drug is unavoidable, gastroprotection is often added and the pain regimen reconsidered.

Citalopram and escitalopram have the cleanest pharmacokinetic profiles because they inhibit CYP enzymes only minimally, so they rarely change the levels of co-prescribed drugs. That is why they are frequently chosen for patients on complex regimens, in oncology, or on drugs with a narrow therapeutic index. Sertraline is close behind, with only mild CYP2D6 inhibition that becomes relevant mainly at higher doses.

The tradeoff for citalopram and escitalopram is QT prolongation. Both have a dose-related effect on the QT interval, and citalopram carries an explicit labeled ceiling: 40 mg per day as the maximum, and 20 mg per day in adults over 60, in hepatic impairment, or when a CYP2C19 inhibitor such as omeprazole is also present. So the SSRI with the fewest pharmacokinetic interactions still needs a QT check when it is stacked on other QT-prolonging drugs or electrolyte disturbance.

Both combinations raise serotonin syndrome risk, and both are extremely common, which is what makes them worth naming specifically. Tramadol is itself serotonergic and, separately, is a CYP2D6 substrate, so fluoxetine or paroxetine can both increase serotonin syndrome risk and reduce tramadol's analgesic conversion at the same time. Triptans used for migraine add serotonergic activity as well; in practice the combination is used frequently and usually tolerated, but it warrants counseling on the symptoms and caution when doses are high or multiple serotonergic drugs stack.

Serotonin syndrome is a spectrum, not a single event. Mild cases show tremor, sweating and hyperreflexia; severe cases show hyperthermia, clonus, rigidity and autonomic instability. The point of an interaction check is not to forbid every serotonergic pairing, which would make many patients untreatable, but to make the additive risk visible so the clinician can weigh it and counsel the patient on what to watch for.

A per-agent table like the one above is useful for pattern recognition and useless when the patient in front of you is on an SSRI, an NSAID, a triptan and a beta-blocker and you are deciding what to add. Prescriber.io takes the actual regimen, checks it for drug-drug interactions, and returns the flag with the mechanism in plain language and the source cited, alongside contraindications, serotonin syndrome combinations, QT burden, and renal and hepatic dose considerations, in one card rather than several separate lookups.

It is decision-support for licensed US clinicians, not autonomous prescribing. Every flag is a prompt for you to consider. You verify against the official labeling and your own institutional references, exercise clinical judgment, and sign. The value is that the check happens on every prescription, including the routine antidepressant refill that turns out to sit on top of a tamoxifen or a warfarin.